Table 1 Multivariate analysis for normalization of lymphocyte subpopulations by day +180/IgG levels at two years after allo-HCT.

From: Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning

 

CD3+/CD4+ lymphocytes normalized by day +180

CD3+/CD8+ lymphocytes normalized by day +180

CD19+ lymphocytes normalized by day +180

IgG normalized at two years

 

HR (95% CI for HR)

p-value

HR (95% CI for HR)

p-value

HR (95% CI for HR)

p-value

HR (95% CI for HR)

P-value

Sex female vs. male

0.83 (0.44–1.57)

0.565

0.92 (0.67–1.27)

0.624

1.21 (0.83–1.76)

0.329

1.13 (0.85–1.50)

0.415

FluTBI vs. FluTreo

3.42 (1.12–10.49)

0.031

1.02 (0.65–1.60)

0.944

0.81 (0.48–1.39)

0.448

1.54 (1.03–2.30)

0.034

Age > 60 years before allo-HCT

0.51 (0.25–1.05)

0.069

0.88 (0.60–1.28)

0.498

1.14 (0.72–1.81)

0.581

1.01 (0.72–1.42)

0.938

Diagnosis AML vs. MDS

0.68 (0.28–1.69)

0.409

1.12 (0.75–1.69)

0.576

1.10 (0.69–1.74)

0.693

1.18 (0.87–1.61)

0.280

ECOG PS (0-1 vs. >1)

0.44 (0.14–1.34)

0.150

0.54 (0.32–0.93)

0.025

1.15 (0.61–2.15)

0.672

1.19 (0.85–1.65)

0.314

HCT-CI score grouped (0–2, 3–5, >5)

1.47 (0.80–2.71)

0.214

1.03 (0.79–1.34)

0.819

0.89 (0.65–1.21)

0.457

0.74 (0.58–0.93)

0.011

Patient CMV− (vs. CMV+)

2.05 (0.93–4.53)

0.076

1.12 (0.80–1.59)

0.507

0.96 (0.64–1.46)

0.861

1.20 (0.87–1.64)

0.263

Donor CMV− (vs. CMV+)

3.16 (1.48–6.75)

0.003

1.78 (1.26–2.51)

0.001

1.07 (0.72–1.60)

0.734

0.91 (0.67–1.24)

0.560

Complex karyotype (no vs. yes)

2.49 (0.97–6.41)

0.058

1.05 (0.69–1.61)

0.818

0.50 (0.28–0.90)

0.021

0.99 (0.85–1.15)

0.884

Donor: M(M)UD vs. matched-RD

1.18 (0.32–4.29)

0.803

1.17 (0.72–1.92)

0.528

2.78 (1.38–5.58)

0.004

0.78 (0.52–1.17)

0.229

Age of donor at allo-HCT (continuous)

1.03 (0.99–1.07)

0.128

1.01 (1.0–1.02)

0.173

1.00 (0.99–1.02)

0.646

0.99 (0.97–1.00)

0.073

MRD positive before allo-HCT (no vs. yes)

0.94 (0.42–2.10)

0.879

1.23 (0.83–1.82)

0.306

1.01 (0.65–1.58)

0.959

0.96 (0.91–1.01)

0.144

In-vivo T-cell depletion (no vs. yes)

0.26 (0.07–0.91)

0.035

1.66 (0.95–2.91)

0.077

1.90 (0.99–3.65)

0.053

1.03 (0.51–2.08)

0.945

Tac vs CSA

5.57 (0.52–59.47)

0.155

1.13 (0.14-8.90)

0.906

0.0000002 (0-Inf)

0.994

3.22 (0.74–13.99)

0.119

Days until first stop of IS (continuous)

1 (1–1)

0.644

1 (1–1)

0.333

1 (1–1)

0.851

1 (1–1)

0.783

IS at day +180 (yes vs. no)

0.80 (0.35–1.83)

0.592

1.10 (0.73–1.65)

0.646

1.01 (0.65–1.59)

0.95

1.73 (1.19–2.51)

0.004

IS at two years (yes vs. no)

0.41 (0.16–1.03)

0.057

1.12 (0.69–1.84)

0.641

0.60 (0.35–1.01)

0.054

1.05 (0.68–1.62)

0.815

  1. HR hazard ratio, CI confidence interval, allo-HCT allogeneic hematopoietic stem cell transplantation, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, ECOG Eastern Cooperative Oncology Group score, PS Performance Score, HCT-CI hematopoietic cell transplantation-specific comorbidity index, CMV cytomegalovirus, MUD matched unrelated donor, MMUD mismatched unrelated donor, matched-RD matched related donor, MRD measurable residual disease, Tac Tacrolimus, CSA Ciclosporin A, IS systemic immunosuppression.
Back to article page